CompletedPhase 1ACTRN12605000522617

A phase I pharmacokinetic study to compare the steady-state pharmacokinetics of testosterone following application of a Testosterone Metered-Dose Transdermal Spray (MDTS) to the forearm or abdomen in healthy postmenopausal women with low libido and low serum testosterone


Sponsor

FemPharm Pty Ltd and/or Acrux DDS Pty Ltd

Enrollment

14 participants

Start Date

Aug 8, 2002

Study Type

Interventional

Conditions


Eligibility

Sex: FemalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This is an early-phase study looking at: A phase I pharmacokinetic study to compare the steady-state pharmacokinetics of testosterone following application of a Testosterone Metered-Dose Transdermal Spray (MDTS) to the forearm or abdomen in healthy postmenopausal women with low libido and low serum testosterone. It may be open to women aged 18 and older. Key requirements include: Healthy post-menopausal women Participation typically involves medical assessments and follow-up visits as part of the research.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Testosterone Metered-Dose Transdermal Spray (MDTS), 5-days.

Testosterone Metered-Dose Transdermal Spray (MDTS), 5-days.


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000522617